Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Adds New Co-Primary Endpoint For Female Sexual Desire Drugs

Executive Summary

Draft guidance says 'associated distress' may replace number of satisfying sexual events as a co-primary efficacy endpoint.

Advertisement

Related Content

Will Palatin's Phase III Female Sex Endpoint Swap Pass With FDA?
FDA Reviewers Disagreed About Approval Of Sprout's Addyi
In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication
Timing Better For Sprout’s Latest Shot At First Female Sex Desire Drug
A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel